Consequently, these findings have informed a strategy of tapering the intensity of DAPT over time, wherein potent P2Y12 inhibitors are administered during the acute phase of acute coronary syndrome, and clopidogrel is utilized during the chronic treatment period (Kim et al., 2021). This evidence concerns the gene P2RY12 and acute coronary syndrome.